1. Home
  2. ATYR vs CSBR Comparison

ATYR vs CSBR Comparison

Compare ATYR & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.73

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Logo Champions Oncology Inc.

CSBR

Champions Oncology Inc.

HOLD

Current Price

$6.76

Market Cap

90.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATYR
CSBR
Founded
2005
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
90.0M
IPO Year
2015
1986

Fundamental Metrics

Financial Performance
Metric
ATYR
CSBR
Price
$0.73
$6.76
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$8.75
$12.00
AVG Volume (30 Days)
2.0M
23.1K
Earning Date
11-06-2025
12-15-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.17
Revenue
$190,000.00
$58,424,000.00
Revenue This Year
N/A
$4.84
Revenue Next Year
$18,728.88
$11.51
P/E Ratio
N/A
$40.00
Revenue Growth
N/A
9.06
52 Week Low
$0.64
$5.59
52 Week High
$7.29
$11.99

Technical Indicators

Market Signals
Indicator
ATYR
CSBR
Relative Strength Index (RSI) 42.99 50.09
Support Level $0.70 $6.74
Resistance Level $0.76 $7.39
Average True Range (ATR) 0.04 0.57
MACD 0.01 0.03
Stochastic Oscillator 32.21 30.09

Price Performance

Historical Comparison
ATYR
CSBR

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Share on Social Networks: